Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ahz-zinc
2. Beta-alanyl-l-histidinato Zinc
3. Z 103
4. Z-103
5. Zinc Carnosine
6. Zinc L-carnosine
7. Zinc L-carnosine Complex
8. Zinc N-(3-aminopropionyl)histidine
1. 107667-60-7
2. Zinc L-carnosine
3. Beta-alanyl-l-histidinato Zinc
4. Ncgc00181764-01
5. Dsstox_cid_28541
6. Dsstox_rid_82813
7. Dsstox_gsid_48615
8. Chembl3184454
9. Dtxsid7048615
10. Tox21_112950
11. Akos037515832
12. Db09221
13. Cas-107667-60-7
14. E76520
15. 667p607
| Molecular Weight | 290.6 g/mol |
|---|---|
| Molecular Formula | C9H13N4O3Zn- |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 289.027907 g/mol |
| Monoisotopic Mass | 289.027907 g/mol |
| Topological Polar Surface Area | 110 Ų |
| Heavy Atom Count | 17 |
| Formal Charge | -1 |
| Complexity | 265 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Peptic ulcer disease, dyspepsia.
Used to treat/manage peptic ulcer disease or irritation of the gastrointestinal tract by promoting tissue healing by the elimination of free radicals.
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Absorption
Intestinal absorption of L-CAZ was studied in rats by Sano et al. using 14C- and 65Zn-labeled compounds. They suggested that L-CAZ dissociates to its components, L-carnosine and zinc, during intestinal absorption.
Route of Elimination
Intestinal absorption of the drug was examined using 14C- and 65Zn-labeled compounds. Polaprezinc metabolizes into its components, L-carnosine and zinc, during intestinal absorption. It was found that the excretion rates after one administration using 14C-labeled L-CAZ to rats were 4.1% in urine, 13.3% in feces, and 38.8% in exhalation. The study using 65Zn-labeled Paleprozinc were 0.3% in urine and 85.0% in the feces. The absorption rate of zinc is estimated to be approximately 11%.
Excretion rates of polaprezinc after a single administration using 14C-labeled drug to rats are 4.1% in urine, 13.3% in feces, and 38.8% in exhalation, and those using 65Zn-labeled L-CAZ are 0.3% in urine and 85.0% in feces. The absorption rate of zinc is estimated to be about 11%.
The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours.
Polaprezinc increases the expression of various antioxidant enzymes, including superoxide dismutase 1 (SOD-1), SOD-2, heme oxygenase-1 (HO-1), glutathione S-transferase (GST), glutathione peroxidase (GSH-px), peroxidredoxin-1 (PRDX1; PRXI) and PRXD5 (PRXV). This process occurs in the gastric mucosa, defending mucosal cells against reactive oxygen species. This drug inhibits the activity of the transcription factor nuclear factor-kappaB (NF-kB) and decreases the expression of various inflammatory cytokines, including interleukin (IL) 1beta, IL-6, IL-8, and tumor necrosis factor alpha (TNF-a). Polaprezinc also promotes the expression of numerous growth factors, including as platelet-derived growth factor-B (PDGF-B), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), in addition to various heat shock proteins (HSPs), including HSP90, HSP70, HSP60, HSP47, HSP27, and HSP10. This process promotes tissue growth and protects against damage the gastric mucosa.
ABOUT THIS PAGE
A NCGC00181764-01 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NCGC00181764-01, including repackagers and relabelers. The FDA regulates NCGC00181764-01 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NCGC00181764-01 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A NCGC00181764-01 supplier is an individual or a company that provides NCGC00181764-01 active pharmaceutical ingredient (API) or NCGC00181764-01 finished formulations upon request. The NCGC00181764-01 suppliers may include NCGC00181764-01 API manufacturers, exporters, distributors and traders.
click here to find a list of NCGC00181764-01 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The NCGC00181764-01 Drug Master File in Japan (NCGC00181764-01 JDMF) empowers NCGC00181764-01 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the NCGC00181764-01 JDMF during the approval evaluation for pharmaceutical products. At the time of NCGC00181764-01 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of NCGC00181764-01 suppliers with JDMF on PharmaCompass.
NCGC00181764-01 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of NCGC00181764-01 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right NCGC00181764-01 GMP manufacturer or NCGC00181764-01 GMP API supplier for your needs.
A NCGC00181764-01 CoA (Certificate of Analysis) is a formal document that attests to NCGC00181764-01's compliance with NCGC00181764-01 specifications and serves as a tool for batch-level quality control.
NCGC00181764-01 CoA mostly includes findings from lab analyses of a specific batch. For each NCGC00181764-01 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
NCGC00181764-01 may be tested according to a variety of international standards, such as European Pharmacopoeia (NCGC00181764-01 EP), NCGC00181764-01 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NCGC00181764-01 USP).
LOOKING FOR A SUPPLIER?
